The date format must match "dd.mm.YYYY"
A host of dossiers assessed by IQWiG to date have addressed oncology drugs. Despite their significance, other diseases, e.g. Alzheimer dementia, are underrepresented.
IQWiG authors report on the availability of randomized controlled trials (RCTs) of newly approved drugs in trial registries as well as on specific search strategies.
Four dossier assessments in 2017 involving comparisons between immunotherapies and chemotherapies for the same indication. Yet, a comparison of immunotherapies among each other is missing.
In their updated guideline, US oncologists recently recommended the MammaPrint test. Researchers from IQWiG have reacted in a letter to the editor in the Journal of Clinical Oncology.
There is an indication of considerable added benefit in progression up to six months after platinum-based therapy. An added benefit is not proven for progression occurring later.
No added benefit can be derived from the incompletely submitted data for adolescents or adults. The postulated better tolerability is not proven.
There were notably more remissions than under the comparator therapies. In future, the analysis of symptoms should not be limited to improvements at one time point.
Good study design allows identification of the relevant subpopulation, in which prolonged overall survival notably outweighs disadvantages in some side effects.
Only case series without informative value are available for most indications. A plausible mode of action is insufficient to attribute a potential.
IQWiG has attributed a potential for a benefit to a new treatment method according to §137e SGB V. A testing study has been initiated. Numerous other assessments had no consequences.
In the short term, tonsillotomy is associated with less pain, as well as fewer swallowing and sleeping problems, than tonsillectomy. But regrowing tissue can lead to renewed inflammation.
More severe side effects occur under the combination of palbociclib and letrozole in the first-line treatment of postmenopausal women. Data were lacking for other patient groups.
Early screening for SCID combined with infection prophylaxis and subsequent treatment can prevent severe or deadly infections.
Patients in whom the widening of blood vessels by means of percutaneous coronary intervention is planned benefit from the new diagnostic procedure; this is not the case for stable CHD.
In future IQWiG will publish press releases only for selected dossier assessments. A table available in the IQWiG press centre shows all assessment results at a glance.
The dossier contains no data or no suitable data on ROS1-positive, advanced non-small cell lung cancer. Results on ALK-positive tumours are not applicable.
Omitting chemotherapy can lead to more cases of distant metastasis and deaths. It cannot yet be judged whether this risk outweighs the chemotherapy-related burden.
Advantages, e.g. in mortality, notably outweigh the disadvantages in some side effects in comparison with docetaxel. An added benefit over best supportive care is not proven.
The drug combination offers survival advantages, but has also considerable side effects. An added benefit could only be derived in the non-mutant tumour type (KRAS wild type).
Patients survive longer, recurrences occur later, and certain side effects occur less often. Overall, the evidence for late-stage disease is much poorer.
Dr. Anna-Sabine Ernst
+49 221 35685-153
+49 221 35685-158
To save your search result, please copy the link below and paste it into a new tab/window.